Federal Register / Vol. 62, No. 30 / Thursday, February 13, 1997 / Notices 6791

The meetings will be closed in accordance

with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program Nos. 93.306, 93.333, 39.337, 93.393–

93.396, 93.837–93.844, 93.846–93.878,

93.392, 93,893, National Institutes of Health,

HHS)

Dated: February 7, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–3633 Filed 2–12–97; 8:45 am]

BILLING CODE 4140–01–M

Prospective Grant of Exclusive

License: Diagnostic Test for

Alzheimer’s Disease

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i) that the National Institutes

of Health (NIH), Department of Health

and Human Services, is contemplating

the grant of a worldwide, limited field

of use, exclusive license to practice the

inventions embodied in the patents and

patent applications referred to below to

NeuroLogic, Inc. of Washington, D.C.

The patents and patent applications to

be licensed are U.S. Patent No.

5,580,748 issued December 3, 1996 (U.S.

Patent Application Serial No. 08/

056,456 filed May 3, 1993), entitled

‘‘Cell Test for Alzheimer’s Disease,’’ and

all continuation applications, divisional

applications, continuation-in-part

applications, and foreign counterpart

applications related to U.S. Patent

Application Serial No. 08/056,456.

SUPPLEMENTARY INFORMATION: The

prospective exclusive license will be

royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless,

within sixty (60) days from the date of

this published notice, NIH receives

written evidence and argument that

establishes that the grant of the license

would not be consistent with the

requirements of 35 U.S.C. 209 and 37

CFR 404.7.

Alzheimer’s disease (AD) represents

the fourth leading cause of death in the

United States, killing over 100,000

annually, and afflicting some 4 million

Americans and is projected to affect

over 14 million by the year 2050.

Various reports indicate that the

incidence of Alzheimer’s disease

increases with age and estimate that the

prevalence of AD in people over 80

years of age is between 20 and 50%.

Under currently available technology

AD can only be positively diagnosed by

pathological examination of brain tissue

during autopsy in conjunction with a

clinical history of dementia.

Present efforts to diagnosis the disease

have been generally directed to the

identification and detection of

molecules present in blood samples or

in cerebral spinal fluid (CSF). Current

tests for the detection of Alzheimer’s

disease have met with varying degrees

of commercial success. The proposed

technology involves the identification of

Alzheimer’s disease utilizing fibroblast

cells. The method consists of:

Measuring the presence or absence of a

specific potassium channel, measuring

the effect of potassium channel blockers

specific for the 113 pS potassium

channel on intracellular calcium levels,

measuring the increase of intracellular

calcium in response to an activator of

intracellular calcium release in the cells

of a patient, and measuring the amount

of the G-protein, cp20.

ADDRESSES: Requests for a copy of these

patent applications, inquiries,

comments, and other materials relating

to the contemplated license should be

directed to: Stephen L. Finley, Ph.D.,

Technology Licensing Specialist, Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852; Telephone: (301) 496–

7056, ext. 215; Facsimile: (301) 492–

0220. A signed Confidential Disclosure

Agreement will be required to receive a

copy of any pending patent application.

Applications for a license filed in

response to this notice will be treated as

objections to the grant of the

contemplated license. Only written

comments and/or applications for a

license which are received by NIH on or

before April 14, 1997, will be

considered. Comments and objections

submitted in response to this notice will

not be made available for public

inspection, and, to the extent permitted

by law, will not be released under the

Freedom of Information Act, 5 U.S.C.

552.

Dated: February 4, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 97–3530 Filed 2–12–97; 8:45 am]

BILLING CODE 4140–01–M

Substance Abuse and Mental Health

Services Administration

Office for Women’s Services; Notice of

Meeting

Pursuant to Public Law 92–463,

notice is hereby given of the meeting of

the Advisory Committee for Women’s

Services of the Substance Abuse and

Mental Health Services Administration

(SAMHSA) in February 1997.

The meeting of the Advisory

Committee for Women’s Services will

include a discussion of policy and

program issues relating to women’s

substance abuse and mental health

service needs; the SAMHSA fiscal year

1998 budget; resolutions adopted at the

Committee’s September meeting;

consideration of September meeting

minutes; and other policy issues.

A summary of the meeting and/or a

roster of committee members may be

obtained from: Pamela J. McDonnell,

Executive Secretary, Advisory

Committee for Women’s Services, Office

for Women’s Services, SAMHSA,

Parklawn Building, Room 13–99, 5600

Fishers Lane, Rockville, Maryland

20857, Telephone: (301) 443–5184.

Substantive information may be

obtained from the contact whose name

and telephone number is listed below.

Committee Name: Advisory Committee for

Women’s Services.

Meeting Date(s): February 24, 1997.

Place: Room 12–94, Parklawn Building,

5600 Fishers Lane, Rockville, MD 20857.

Open: February 24, 2:00 p.m. to 4:00 p.m.

Contact: Pamela J. McDonnell, Room 13–

99, Parklawn Building, Telephone: (301)

443–5184.

This notice is being published less than 15

days prior to the meeting due to the urgent

need to resolve pending issues before a full

meeting can be scheduled.

Dated: February 7, 1997.

Jeri Lipov,

Committee Management Officer, Substance

Abuse and Mental Health Services

Administration.

[FR Doc. 97–3586 Filed 2–12–97; 8:45 am]

BILLING CODE 4162–20–P

DEPARTMENT OF HOUSING AND

URBAN DEVELOPMENT

[Docket No. FR–4200–N–24]

Notice of Proposed Information

Collection for Public Comment

AGENCY: Office of the Assistant

Secretary for Policy Development and

Research, HUD.

ACTION: Notice.

SUMMARY: The proposed information

collection requirement described below